IN CELL ART and Sanofi Pasteur enter into research collaboration agreement

French biotech company IN CELL ART, which is involved in the development of nanocarriers for macromolecular drug delivery, has entered into a research collaboration agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, to evaluate IN CELL ART nanocarriers technologies in the context of Sanofi Pasteur's vaccines programme.

French biotech company IN CELL ART, which is involved in the development of nanocarriers for macromolecular drug delivery, has entered into a research collaboration agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, to evaluate IN CELL ART nanocarriers technologies in the context of Sanofi Pasteur's vaccines programme.

These new classes of vectors are organised on a nanometric scale, which enables them to cross the cell barrier efficiently and safely. Positive results could lead to the continuation of IN CELL ART nanocarriers" evaluation in Sanofi Pasteur's new vaccines development.

Nantes-based IN CELL ART has expertise in antibody generation using genetic immunisation, allowing for the rapid generation of antibodies to any gene-specific antigen. This technology is particularly suitable for screening applications. The company is also pursuing highly promising approaches in the field of DNA-based therapeutic vaccines, with successful studies in animal models of cancers and infectious diseases.

IN CELL ART works in partnership with pharmaceutical and biotechnology companies and grants licences for its vaccine formulation.

With ongoing r&d programmes in the fields of oncology, cardiovascular diseases and anti-infectives, it also works closely with companies that are active in the development of RNAi therapeutic products for interference with the expression of targeted disease-associated genes. Besides, IN CELL ART works with companies involved in the development of therapeutic proteins for the improvement of pharmacokinetics. In both these areas, IN CELL ART grants licences for its nanocarriers.

Finally, the company is working on the commercialisation of ICAFectin441 and ICAFectin442, which are DNA and siRNA transfection reagents for primary and stem cells.

Companies